Advances in the treatment of achondroplasia
DOI:
https://doi.org/10.12775/JEHS.2025.80.59589Keywords
achondroplasia, FGFR3, skeletal dysplasia, vosoritide, short statureAbstract
Achondroplasia is a condition resulting from a missense mutation in the FGFR3 (fibroblast growth factor receptor 3) gene, representing the predominant etiology of short height in humans. Physical phenotypic characteristics encompass small stature, macrocephaly with frontal bossing, midface hypoplasia, rhizomelic shortening of the limbs, brachydactyly, and genu varum. Untreated cases result in several orthopedic and neurological issues that ultimately lead to impairment. Treatment techniques for achondroplasia can be categorized into surgical and pharmaceutical therapy. Enhanced comprehension of the etiology of this disease has prompted efforts to create causative pharmaceutical treatments. This review introduces innovative possible pharmacological therapies for achondroplasia including vosoritide, which received approval for patient usage in 2021, as well as TransCON CNP, meclozine, infigratinib, and recifercept, all now undergoing clinical trials.
Aim of the study: The main aim of this study is to elucidate the most recent treatment methodologies for patients with achondroplasia. This article presents groundbreaking advancements and new therapies designed to enhance the quality of life for patients with achondroplasia, while also raising awareness of available treatment choices and fostering optimism for future developments in this domain. In 2021, vosoritide (Voxzogo), a C-type natriuretic peptide (CNP) analogue, was approved by the US FDA and EMA for use in children with achondroplasia. As of January 2025, vosoritide therapy has been available in Poland for patients with achondroplasia under the drug program, which is a response to the unmet therapeutic need in patients with achondroplasia.
Materials and methods: A review of the literature available in the PubMed and Google Scholar databases was performed, using the key words: „achondroplasia", „FGFR3”, „skeletal dysplasia", „vosoritide”, „short stature”.
References
[1] Unger S, Ferreira CR, Mortier GR, Ali H, Bertola DR, Calder A, et al. Nosology of genetic skeletal disorders: 2023 revision. Am J Med Genet A 2023;191:1164–209. https://doi.org/10.1002/ajmg.a.63132.
[2] Foreman PK, van Kessel F, van Hoorn R, van den Bosch J, Shediac R, Landis S. Birth prevalence of achondroplasia: A systematic literature review and meta-analysis. Am J Med Genet A 2020;182:2297–316. https://doi.org/10.1002/ajmg.a.61787.
[3] Pnas BE. Advancing age has differential effects on DNA damage, chromatin integrity, gene mutations, and aneuploidies in sperm. vol. 103. 2006.
[4] Hoover-Fong JE, Schulze KJ, Mcgready J, Barnes H, Scott CI. Age-appropriate body mass index in children with achondroplasia: interpretation in relation to indexes of height 1-3. vol. 88. 2008.
[5] Hoover-Fong JE, Alade AY, Hashmi SS, Hecht JT, Legare JM, Little ME, et al. Achondroplasia Natural History Study (CLARITY): a multicenter retrospective cohort study of achondroplasia in the United States. Genetics in Medicine 2021;23:1498–505. https://doi.org/10.1038/s41436-021-01165-2.
[6] Pauli RM. Achondroplasia: A comprehensive clinical review. Orphanet J Rare Dis 2019;14. https://doi.org/10.1186/s13023-018-0972-6.
[7] Neumeyer L, Merker A, Hagenäs L. Clinical charts for surveillance of growth and body proportion development in achondroplasia and examples of their use. Am J Med Genet A 2021;185:401–12. https://doi.org/10.1002/ajmg.a.61974.
[8] Broström EW, Antonissen L, von Heideken J, Esbjörnsson AC, Hagenäs L, Naili JE. Gait in children with achondroplasia – a cross-sectional study on joint kinematics and kinetics. BMC Musculoskelet Disord 2022;23. https://doi.org/10.1186/s12891-022-05343-4.
[9] Calandrelli R, Pilato F, Massimi L, Onesimo R, D’Apolito G, Tenore L, et al. Thoracolumbar stenosis and neurologic symptoms: Quantitative MRI in achondroplasia. Journal of Neuroimaging 2022;32:884–93. https://doi.org/10.1111/jon.13015.
[10] Nakano Y, Kubota T, Ohata Y, Takeyari S, Kitaoka T, Miyoshi Y, et al. Assessment of body fat mass, anthropometric measurement and cardiometabolic risk in children and adolescents with achondroplasia and hypochondroplasia. vol. 2023. n.d.
[11] Akinnusotu O, Isaacs AM, Stone M, Bonfield CM. Neurosurgical management of cervicomedullary compression, spinal stenosis, and hydrocephalus in pediatric achondroplasia: a systematic review. J Neurosurg Pediatr 2023;32:597–606. https://doi.org/10.3171/2023.6.PEDS23162.
[12] Hallan D, Mrowczynski OD, McNutt S, Rizk E. Post-Laminectomy Kyphosis in Achondroplasia Patients: To Concurrently Fuse or Not. Cureus 2020. https://doi.org/10.7759/cureus.7966.
[13] Hoover-Fong J, Cheung MS, Fano V, Hagenas L, Hecht JT, Ireland P, et al. Lifetime impact of achondroplasia: Current evidence and perspectives on the natural history. Bone 2021;146. https://doi.org/10.1016/j.bone.2021.115872.
[14] Nahm NJ, Mackenzie WGS, Mackenzie WG, Gough E, Hashmi SS, Hecht JT, et al. Achondroplasia natural history study (CLARITY): 60-year experience in orthopedic surgery from four skeletal dysplasia centers. Orphanet J Rare Dis 2023;18. https://doi.org/10.1186/s13023-023-02738-x.
[15] Hosny GA. Limb lengthening history, evolution, complications and current concepts. Journal of Orthopaedics and Traumatology 2020;21. https://doi.org/10.1186/s10195-019-0541-3.
[16] Verdoni F, Giorgino R, Virgilio C, Nannini A, Viganò M, Curci D, et al. Results and complications of bilateral limb lengthening in achondroplasia: a retrospective analysis. Front Pediatr 2023;11. https://doi.org/10.3389/fped.2023.1281099.
[17] Constantinides C, Landis SH, Jarrett J, Quinn J, Ireland PJ. Quality of life, physical functioning, and psychosocial function among patients with achondroplasia: a targeted literature review. Disabil Rehabil 2022;44:6166–78. https://doi.org/10.1080/09638288.2021.1963853.
[18] Laufer A, Rölfing JD, Gosheger G, Toporowski G, Frommer A, Roedl R, et al. What Are the Risks and Functional Outcomes Associated With Bilateral Humeral Lengthening Using a Monolateral External Fixator in Patients With Achondroplasia? Clin Orthop Relat Res 2022;480:1779–89. https://doi.org/10.1097/CORR.0000000000002209.
[19] Saint-Laurent C, Garde-Etayo L, Gouze E. Obesity in achondroplasia patients: From evidence to medical monitoring. Orphanet J Rare Dis 2019;14. https://doi.org/10.1186/s13023-019-1247-6.
[20] Kim D, Yoon J, Suh MW, Lee JH, Kyun Park M. Otologic Manifestations in Patients with Achondroplasia: A Multicenter Study. Journal of International Advanced Otology 2024;20:517–22. https://doi.org/10.5152/iao.2024.241523.
[21] White KK, White KK, Bober MB, Cho TJ, Goldberg MJ, Goldberg MJ, et al. Best practice guidelines for management of spinal disorders in skeletal dysplasia. Orphanet J Rare Dis 2020;15. https://doi.org/10.1186/s13023-020-01415-7.
[22] Maghnie M, Semler O, Guillen-Navarro E, Selicorni A, Heath KE, Haeusler G, et al. Lifetime impact of achondroplasia study in Europe (LIAISE): findings from a multinational observational study. Orphanet J Rare Dis 2023;18. https://doi.org/10.1186/s13023-023-02652-2.
[23] Krstevska-Konstantinova M, Stamatova A, Gucev Z. Favorable Growth Hormone Treatment Response in a Young Boy with Achondroplasia. Med Arch 2016;70:148–50. https://doi.org/10.5455/medarh.2016.70.148-150.
[24] Tanaka T. Clinical Pediatric Endocrinology Review History of GH treatment in Japan 2022. https://doi.org/10.1297/cpe.31.2021-0044.
[25] Yasoda A, Ogawa Y, Suda M, Tamura N, Mori K, Sakuma Y, et al. Natriuretic peptide regulation of endochondral ossification: Evidence for possible roles of the C-type natriuretic peptide/guanylyl cyclase-B pathway. Journal of Biological Chemistry 1998;273:11695–700. https://doi.org/10.1074/jbc.273.19.11695.
[26] Mackie EJ, Ahmed YA, Tatarczuch L, Chen KS, Mirams M. Endochondral ossification: How cartilage is converted into bone in the developing skeleton. International Journal of Biochemistry and Cell Biology 2008;40:46–62. https://doi.org/10.1016/j.biocel.2007.06.009.
[27] Kerkelä R, Ulvila J, Magga J. Natriuretic peptides in the regulation of cardiovascular physiology and metabolic events. J Am Heart Assoc 2015;4. https://doi.org/10.1161/JAHA.115.002423.
[28] Wrobel W, Pach E, Ben-Skowronek I. Advantages and disadvantages of different treatment methods in achondroplasia: A review. Int J Mol Sci 2021;22. https://doi.org/10.3390/ijms22115573.
[29] Mindler GT, Stauffer A, Chiari C, Mladenov K, Horn J. Achondroplasia current concept of orthopaedic management. J Child Orthop 2024. https://doi.org/10.1177/18632521241269340.
[30] Kake T, Kitamura H, Adachi Y, Yoshioka T, Watanabe T, Matsushita H, et al. Chronically elevated plasma C-type natriuretic peptide level stimulates skeletal growth in transgenic mice. Am J Physiol Endocrinol Metab 2009;297:1339–48. https://doi.org/10.1152/ajpendo.00272.2009.-C.
[31] Semler O, Cormier-Daire V, Lausch E, Bober MB, Carroll R, Sousa SB, et al. Vosoritide Therapy in Children with Achondroplasia: Early Experience and Practical Considerations for Clinical Practice. Adv Ther 2024;41:198–214. https://doi.org/10.1007/s12325-023-02705-9.
[32] Savarirayan R, Irving M, Bacino CA, Bostwick B, Charrow J, Cormier-Daire V, et al. C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia. New England Journal of Medicine 2019;381:25–35. https://doi.org/10.1056/nejmoa1813446.
[33] Hoover-Fong J, Savarirayan R, Irving M, Wr W, Ca B, Mb B, et al. Persistent and stable growth promoting effects of vosoritide in children with achondroplasia for up to 3.5 years: results from an ongoing Phase 3 extension study. n.d.
[34] Savarirayan R, Tofts L, Irving M, Wilcox WR, Bacino CA, Hoover-Fong J, et al. Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study. Genetics in Medicine 2021;23:2443–7. https://doi.org/10.1038/s41436-021-01287-7.
[35] Fafilek B, Bosakova M, Krejci P. Expanding horizons of achondroplasia treatment: current options and future developments. Osteoarthritis Cartilage 2022;30:535–44. https://doi.org/10.1016/j.joca.2021.11.017.
[36] Matsushita M, Kitoh H, Ohkawara B, Mishima K, Kaneko H, Ito M, et al. Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia. PLoS One 2013;8. https://doi.org/10.1371/journal.pone.0081569.
[37] Kitoh H, Matsushita M, Mishima K, Nagata T, Kamiya Y, Ueda K, et al. Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia. PLoS One 2020;15. https://doi.org/10.1371/journal.pone.0229639.
[38] Gonçalves D, Rignol G, Dellugat P, Hartmann1 G, Garcia SS, Stavenhagen J, et al. In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia. PLoS One 2020;15. https://doi.org/10.1371/journal.pone.0244368.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Patrycja Jędrzejewska-Rzezak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 130
Number of citations: 0
